Myriad Genetics (MYGN) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq futures sink as Amazon, Intel intensify AI spending fears
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $6.67 --0%
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
BNCC, ZVOI, SYRS, More
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
BNCC, ZVOI, SYRS, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of ($0.03), $0.05 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $191.9 million versus the consensus estimate of $179.23 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chevron beats estimates as refining margins lift earnings
- Sensient Technologies (SXT) Tops Q3 EPS by 4c, Misses on Revenue; Offers FY26 EPS Guidance
- Dominion Energy (D) Tops Q3 EPS by 9c, Beats on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
